Kadcyla
Seagen’s Tukysa Demonstrates Trial Victory in Breast Cancer, Amplifying Roche’s Kadcyla and Significance in Light of Pfizer’s $43B Acquisition
Anika Sharma
In a strategic move, Pfizer has announced a hefty investment of $43 billion to acquire Seagen, with a keen focus ...
Daiichi Sankyo to Dominate Antibody-Drug Conjugates Market by 2029
SG Tylor
Daiichi has successfully established ADCs (Antibody-Drug Conjugates) as a significant therapeutic approach, overcoming previous years of underwhelming results. Even though ...
